Overview PharmaTrace is at the forefront of revolutionizing the healthcare ecosystem by seamlessly integrating blockchain, AI, and machine learning (ML) technologies. The platform addresses critical challenges in pharmaceutical supply chain…
From Frustration to Innovation; Decoding the Complexities of Biology The complexities of biology present significant challenges in the discovery and development of new medicines, and this has resulted in the…
Imagine a world where every patient receives the right treatment, at the right time, every time. No more trial and error, no more suffering through ineffective medications. This might sound…
Absci’s Integrated Drug Creation™ platform begins with the Data to Train. Absci is a biotechnology company focused on revolutionizing drug discovery through the innovative use of generative artificial intelligence (AI).…
Insilico Medicine is a biotechnology company that focuses on using generative AI for drug discovery and development with the aim of significantly reducing the time and cost required to bring…
Welcome to the thrilling universe where artificial intelligence (AI) meets the intricate world of drug discovery. Your decision to step into this realm of boundless possibilities deserves commendation, and celebrating…
The transformative potential of artificial intelligence (AI) in drug discovery is becoming clearer more than ever before. AI-powered systems are helping to accelerate the identification of promising drug candidates, optimize…
In recent years, artificial intelligence (AI) is revolutionizing various industries, and healthcare has not been left out. The drug discovery process, while crucial for developing life-saving treatments, is notoriously time-consuming…
Drug Name: Truqap Active Ingredient: capivasertib Indication: An AKT inhibitor used in combination with fulvestrant for the treatment of advanced HR-positive breast cancer Approval Date: 11/16/2023 Company: AstraZeneca More: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer
Drug Name: Augtyro Active Ingredient: repotrectinib Indication: To treat ROS1-positive non-small cell lung cancer Approval Date: 11/15/2023 Company: Bristol-Myers Squibb Company More: https://accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf